



# Adrenal Hormone Report; saliva


**Order:** SAMPLE REPORT**Client #:** 12345**Doctor:** Sample Doctor  
Doctor's Data, Inc.  
3755 Illinois Ave.  
St. Charles, IL 60174**Patient:** Sample Patient**Age:** 35**Sex:** Female**Menopausal Status:** Pre-menopausal**Sample Collection****Date Collected****Date Received****Date Reported****Date/Time**

11/29/2021

11/30/2021

12/01/2021

Analyte	Result	Unit	L	WRI	H	Optimal Range	Reference Interval
Cortisol AM30	7.4	nmol/L		◆		14.0 – 25.0	7.0 – 30.0
Cortisol Noon	3.4	nmol/L		◆		5.0 – 10.0	2.1 – 14.0
Cortisol Evening	0.50	nmol/L	↓			2.0 – 5.0	1.5 – 8.0
Cortisol Night	1.2	nmol/L		◆		1.0 – 4.0	0.33 – 7.0
DHEA*	89	pg/mL	↓				106 – 300

**Cortisol Graph****Hormone Comments**

- Diurnal cortisol pattern is consistent with evolving (Phase 2) HPA axis (adrenal gland) dysfunction.
- DHEA levels typically decline with age and the level measured here is below the reference range. Note: Supplementation with DHEA may increase testosterone and/or estradiol levels.

**Adrenal Phase: 2****Notes:**

The current samples are routinely held three weeks from receipt for additional testing.

*RI= Reference Interval, L (blue)= Low (below RI), WRI (green)= Within RI (optimal), WRI (yellow)= Within RI (not optimal), H (red)= High (above RI)*

\*This test was developed and its performance characteristics determined by Doctor's Data Laboratories in a manner consistent with CLIA requirements. The U. S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA clearance is not currently required for clinical use. The results are not intended to be used as a sole means for clinical diagnosis or patient management decisions.

Methodology: Enzyme Immunoassay



# Hormone Report; saliva

**Order:** SAMPLE REPORT**Client #:** 12345**Doctor:** Sample Doctor

Doctor's Data, Inc.

3755 Illinois Ave.

St. Charles, IL 60174

**Patient:** Sample Patient**Age:** 35**Sex:** Female**Menopausal Status:** Pre-menopausal**Sample Collection****Date Collected****Date/Time**

11/29/2021

**Date Received**

11/30/2021

**Date Reported**

12/01/2021

Analyte	Result	Unit	L	WRI	H	Reference Interval	Supplementation Range**
Estradiol (E2)	1.8	pg/mL		◆		0.6 – 4.5	1.0 – 6.0
Progesterone (Pg)	115	pg/mL	↓			127 – 446	400 – 4000
Pg/E2 Ratio†	63.9		↓			≥ 200	≥ 200
Testosterone	15	pg/mL		◆		6 – 49	25 – 60
DHEA*	89	pg/mL	↓			106 – 300	



## Hormone Comments

- Progesterone to estradiol (Pg/E2) ratio is consistent with progesterone insufficiency (estrogen dominance). Supplementation with progesterone to correct this relative deficiency is a consideration depending on the clinical picture. Note: The progesterone level is suggestive of an anovulatory cycle or luteal phase defect. Query BCP usage.
- DHEA levels typically decline with age and the level measured here is below the reference range. Note: Supplementation with DHEA may increase testosterone and/or estradiol levels.
- Supplementation reference ranges are based on adherence to proper dosage interval(s). Please visit <https://www.DoctorsData.com/Resources/BestPractices.pdf> for more information.

**Notes:**

The current samples are routinely held three weeks from receipt for additional testing.

RI= Reference Interval, L (blue)= Low (below RI), WRI (green)= Within RI (optimal), WRI (yellow)= Within RI (not optimal), H (red)= High (above RI)

\*This test was developed and its performance characteristics determined by Doctor's Data Laboratories in a manner consistent with CLIA requirements. The U. S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA clearance is not currently required for clinical use. The results are not intended to be used as a sole means for clinical diagnosis or patient management decisions.

†The Pg/E2 ratio is an optimal range established based on clinical observation. Reference intervals for Pg/E2 ratio have not been established in males and post-menopausal women who are not supplementing with progesterone and/or estrogens.

\*\*If supplementation is reported then the supplementation ranges will be graphed. The supplementation ranges depicted are for informational purposes only and were derived from a cohort of adult men and women utilizing physiologic transdermal bioidentical hormone therapy.

Methodology: Enzyme Immunoassay